Statin treatment and mortality: Propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Laidler, Matthew R ^a   Thomas, Ann ^a   Baumbach, Joan ^b   Kirley, Pam Daily ^c   Meek, James ^d   Aragon, Deborah ^e   Morin, Craig ^f   Ryan, Patricia A ^g   Schaffner, William ^h   Zansky, Shelley M ⁱ   Chaves, Sandra S ^j  

^a OREGON HEALTH AUTHORITY   (United States)

^b NEW MEXICO DEPARTMENT OF HEALTH   (United States)

^c CALIFORNIA EMERGING INFECTIONS PROGRAM   (United States)

^d YALE UNIVERSITY   (United States)

^e Colorado Department of Public Health and Environment ^*  (United States)

^f MINNESOTA DEPARTMENT OF HEALTH   (United States)

^g MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

Immunomodulatory agents; Influenza; Influenza mortality; Pandemic; Pandemic H1N1; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL FEATURE; DRUG USE; EPIDEMIC; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROPENSITY SCORE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; VERY ELDERLY;

EID: 84978328531     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv028     Document Type: Article

References (36)

1. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PloS One 2013; 8:e66312.
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
3. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62.
4. Reichert TA, Simonsen L, Sharma A, et al. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 2004; 160:492-502.
5. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945-52.
6. Simonsen L, Spreeuwenberg P, Lustig R, et al. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study. PLoS Med 2013; 10:e1001558.
7. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277-9.
8. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510-5.
9. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75.
10. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198-204.
11. Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553-63.
12. Chaves SS, Aragon D, Bennett N, et al. Patients hospitalized with laboratory-confirmed influenza during the 2010-2011 influenza season: exploring disease severity by virus type and subtype. J Infect Dis 2013; 208:1305-14.
13. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43:199-205.
14. Fedson DS. How will physicians respond to the next influenza pandemic? Clin Infect Dis 2014; 58:233-7.
15. McGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 2007; 98:163-75.
16. Merx MW, Weber C. Statins in the intensive care unit. Curr Opin Crit Care 2006; 12:309-14.
17. Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Crit Care 2006; 10:113.
18. Almog Y, Novack V, Eisinger M, et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35:372-8.
19. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110:880-5.
20. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367:413-8.
21. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169:1658-67.
22. Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and inhospital severity of 2009 pandemic influenza A(H1N1) disease. PloS One 2011; 6:e18120.
23. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205:13-9.
24. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131:1006-12.
25. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PloS One 2009; 4:e8087.
26. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399-424.
27. Parsons L. Performing a 1:N case-control match on propensity score. In: Proceedings of the 29th Annual SAS Users Group International Conference, Cary, NC. SAS Institute, 2004.
28. Rosenbaum PR. Observational Studies. 2nd ed. New York: Springer, 2002.
29. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Available at: http://www.openepi.com. Accessed 20 December 2013.
30. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-402.
31. Viasus D, Pano-Pardo JR, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62:193-9.
32. Papazian L, Roch A, Charles PE, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013; 310:1692-700.
33. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370:2191-200.
34. Peng J, Zhang D, Ma Y, et al. Protective effect of fluvastatin on influenza virus infection. Mol Med Rep 2014; 9:2221-6.
35. Jackson LA, Nelson JC. Association between statins and mortality. J Infect Dis 2012; 206:303-4; author reply 4-5.
36. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipidlowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166:348-54.